Anzeige
Mehr »
Freitag, 05.09.2025 - Börsentäglich über 12.000 News
SuperBuzz x Prymatica: Ein Vertriebsdeal, der KI-Hype in B2B-Umsätze verwandeln könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3E2GA | ISIN: BMG0360L1349 | Ticker-Symbol:
NASDAQ
19.12.24 | 21:44
0,300 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ALTAMIRA THERAPEUTICS LTD Chart 1 Jahr
5-Tage-Chart
ALTAMIRA THERAPEUTICS LTD 5-Tage-Chart

Aktuelle News zur ALTAMIRA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
29.08.Altamira Therapeutics Ltd. - 6-K, Report of foreign issuer5
29.08.Altamira Therapeutics Provides Business Update and First Half 2025 Financial Results514Company to host webcast today at 8.00 a.m. ETGrowing portfolio of RNA delivery clients and programsAdvancing plans for partial spin-off of RNA delivery activitiesContinued adjustment of cost structure...
► Artikel lesen
26.08.Altamira Therapeutics to Host First Half 2025 Financial Results and Business Update Call on August 29, 2025214HAMILTON, BERMUDA / ACCESS Newswire / August 26, 2025 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCQB:CYTOF), a company dedicated to developing and commercializing RNA delivery technology...
► Artikel lesen
15.07.Altamira Therapeutics Ltd.: Altamira Therapeutics Announces Allowance of Japanese Patent Application Covering Intranasal Betahistine133HAMILTON, BM / ACCESS Newswire / July 15, 2025 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCQB:CYTOF), a company dedicated to developing therapeutics that address important unmet medical...
► Artikel lesen
17.06.NSE - Altamira Therapeutics Ltd. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities2
ALTAMIRA THERAPEUTICS Aktie jetzt für 0€ handeln
11.06.Altamira Therapeutics Ltd. - 6-K, Report of foreign issuer1
11.06.Delisting of Securities of Blue Star Foods Corp.; Altamira Therapeutics Ltd.; Evergreen Corporation; Fresh2 Group Limited; Coliseum Acquisition Corp.; The Real Good Food Company, Inc.; Mynaric AG; byNordic Acquisition Corporation; ...669NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock of Blue Star Foods Corp. Blue Star Foods Corp.'s stock was suspended on December...
► Artikel lesen
09.05.Altamira Therapeutics Ltd. - 6-K, Report of foreign issuer1
30.04.Altamira Therapeutics Ltd. - 20-F, Annual and transition report of foreign private issuers5
30.04.Altamira Therapeutics Ltd: Altamira Therapeutics Provides Business Update, Reports Full Year 2024 Financial Results289Hamilton, Bermuda, April 30, 2025 (GLOBE NEWSWIRE) -- Management to host conference call today, April 30, at 8:00 a.m. EDTRNA delivery business progressing with platform development, new applications...
► Artikel lesen
30.04.Altamira Therapeutics Ltd. - 6-K, Report of foreign issuer1
25.04.Altamira Therapeutics Ltd: Altamira Therapeutics to Host Full Year 2024 Financial Results and Business Update Call on April 30, 20251
04.04.Altamira Therapeutics Ltd. - S-8, Securities to be offered to employees in employee benefit plans2
10.03.Altamira Therapeutics Ltd. - 6-K, Report of foreign issuer3
22.01.Altamira Therapeutics Ltd: Altamira Therapeutics Announces Collaboration on Radiopharmaceutical Targeting Strategies224Hamilton, Bermuda, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Exploring use of Altamira's RNA nanoparticles in conjunction with radiopharmaceutical cancer treatment Project collaboration partner will have...
► Artikel lesen
31.12.24Altamira Therapeutics Ltd: Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA268Hamilton, Bermuda, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Further proof of great versatility of Altamira's platform for extrahepatic RNA deliveryCircular mRNA significantly increasing protein expression...
► Artikel lesen
20.12.24Altamira Therapeutics Ltd: Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets456HAMILTON, BERMUDA, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Trading to continue under ticker symbol "CYTOF"No reverse stock split planned Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCQB:...
► Artikel lesen
04.10.24Altamira Therapeutics Ltd: Altamira Therapeutics Provides Update on Nasdaq Listing352Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO) today announced that it received on September 30, 2024, a letter from the...
► Artikel lesen
24.09.24Altamira Therapeutics Ltd: Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results282Hamilton, Bermuda, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Company to host conference call today at 8.30 a.m. ETContinued progress within core activities in RNA delivery, supported by move into new...
► Artikel lesen
16.09.24Altamira Therapeutics Ltd: Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia202Hamilton, Bermuda, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Nuance Pharma successfully launched Bentrio® nasal spray for protection against airborne particles in Hong Kong and filed request for marketing...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1